Shares of cannabis stocks slumped after a company set to testify in the Drug Enforcement Administration's rescheduling hearings accused the agency of obstructing the rulemaking process.
Advocates accuse Drug Enforcement Administration of blocking the reclassification of cannabis as a Schedule III drug under the Controlled Substances Act.